NASDAQ:IDYA IDEAYA Biosciences Q2 2026 Earnings Results & Report $34.26 -1.80 (-4.99%) Closing price 04:00 PM EasternExtended Trading$34.90 +0.64 (+1.88%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. IDEAYA Biosciences missed analyst earnings expectations but beat on revenue in its Q2 2026 results, released August 4, 2026. The company reported EPS of -$1.22 versus the -$1.06 consensus estimate, while revenue of $8.86 million topped the $8.02 million estimate by $0.84 million. Revenue increased 8,800.0% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 4, 2026TimeBefore Market OpensConference Call6:00 AM ET IDEAYA Biosciences EPS ResultsActual EPS-$1.22Consensus EPS -$1.06Beat/MissMissed by -$0.16One Year Ago EPS-$0.88EPS Beat Rate3 of last 8 quartersIDEAYA Biosciences Revenue ResultsActual Revenue$8.86 millionExpected Revenue$8.02 millionBeat/MissBeat by +$837.00 thousandYoY Revenue Growth+8,800.00%Upcoming EarningsIDEAYA Biosciences' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) IDEAYA Biosciences Q2 2026 Earnings FAQ Did IDEAYA Biosciences beat earnings estimates for Q2 2026? IDEAYA Biosciences (NASDAQ:IDYA) reported earnings of -$1.22 per share for Q2 2026, missing the consensus estimate of -$1.06. The report was announced on Tuesday, August 4, 2026. What was IDEAYA Biosciences' revenue for Q2 2026? IDEAYA Biosciences reported revenue of $8.86 million for Q2 2026, against a consensus estimate of $8.02 million. When is IDEAYA Biosciences' next earnings date? IDEAYA Biosciences' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for IDEAYA Biosciences on the company's earnings history page. IDEAYA Biosciences Earnings HeadlinesIDEAYA Biosciences (NASDAQ:IDYA) vs. Sangamo Therapeutics (NASDAQ:SGMO) Head to Head ReviewOctober 8, 2026 | americanbankingnews.comIDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and DevelopmentSeptember 28, 2026 | prnewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.October 13 at 1:00 AM | Profits Run (Ad)Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?September 25, 2026 | insidermonkey.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 25, 2026 | prnewswire.comAnalysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), IDEAYA Biosciences (IDYA)September 19, 2026 | theglobeandmail.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancer. The company uses insights from tumor biology, cancer genetics and synthetic lethality to identify treatments designed to target specific molecular alterations in tumors. Its development pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily in genetically defined cancers, including GNAQ- or GNA11-mutated uveal melanoma. IDEAYA is also developing IDE397, an investigational MAT2A inhibitor intended for cancers with MTAP deletions, along with additional discovery and development programs targeting genetically selected tumors. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA conducts research and clinical development activities through collaborations and clinical studies intended to serve patients in multiple international markets. The company’s programs remain investigational, and their safety and effectiveness have not been established for general use.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
